RNGTT is a bifunctional mRNA-capping enzyme exhibiting RNA 5-triphosphatase activity in the N-terminal part and mRNA guanylyltransferase activity in the C-terminal part. The protein catalyzes the first two steps of cap formation: by removing the gamma-phosphate from the 5-triphosphate end of nascent mRNA to yield a diphosphate end, and by transferring the gmp moiety of GTP to the 5-diphosphate terminus.
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target:
The synthetic peptide sequence used to generate the antibody AP6617b was selected from the C-term region of human RNGTT. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
* VAT and and shipping costs not included. Errors and price changes excepted
